For allergen immunotherapy, key is the size of the dose, not the amount used

Why This Topic Matters

Allergen immunotherapy claims are sensitive to how services are split, documented, and matched to payer rules. Understanding the broader policy landscape helps reduce denials and supports consistent reporting across Medicare and commercial payer scenarios.

Article Sections

1. Antigen preparation billing and dose-based unit reporting

   Introduces billing considerations for antigen preparation services and explains the general relationship between prepared doses and reported units. The section frames the issue in the context of Medicare and common denial patterns.

2. Separate reporting of preparation, provision, and injection services

   Covers how antigen supervision and injection services are reported separately and references Medicare guidance and contractor policy. It also notes related considerations for service bundling and payer-specific restrictions.

3. Carrier policies, limits, and place-of-service rules

   Describes how local and commercial payer policies may affect allowed units, documentation expectations, and site-of-service coverage. The section highlights that policies can vary by payer and setting.

4. Understanding dose definitions and reporting for immunotherapy services

   Addresses how dose-related reporting is discussed in the article and how coding decisions are tied to the service being furnished. It also includes Medicare considerations for related antigen preparation services.

5. Testing results and evaluation and management reporting

   Explains how testing-related services may include results communication and when separate evaluation and management reporting is discussed. The section also references related allergy testing coding concepts and documentation concerns.